Androgenetic alopecia (male pattern hair loss) in the United States: what treatments should primary care providers recommend?
Androgenetic alopecia (AGA), or male pattern hair loss, affects up to 96% of Caucasian men. Characterized by gradual thinning and eventual loss of hair along frontotemporal, parietal, and vertex areas of the scalp, AGA is associated with low self-esteem, depression, and dissatisfaction with body appearance. In this systematic review of the literature, six primary research studies conducted in the United States are evaluated for their clinical application to primary care provider practice. Topical minoxidil 2%-5% 1 mL twice daily or finasteride 1 mg daily are recommended as first line treatments, followed by the use of Food and Drug Administration-cleared HairMax LaserComb® in patients who do not respond to first line modalities. Further research in novel and established treatments is recommended, along with an evidence-based clinical practice guideline for practitioners in the United States.